Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
April 30 2024 - 4:01PM
Galapagos’ shareholders adopt all resolutions proposed by the Board
of Directors at the Annual and Extraordinary Shareholders Meetings
2024
Mechelen, Belgium; 30 April 2024, 22:01
CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces
that all resolutions proposed at the company’s Annual and
Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April
2024 were approved.
The AGM approved, amongst other items:
- The Remuneration Report and revised
Remuneration Policy
- The remuneration of the members of
the Board of Directors
- The reappointment of Dr. Elisabeth
Svanberg as Independent Non-Executive Director
- The appointments of Dr. Susanne
Schaffert and Mr. Simon Sturge as Independent Non-Executive
Directors and Mr. Andrew Dickinson as Non-Executive Director
- The charging of the statutory
auditor with respect to the “assurance” of the CSRD sustainability
reporting
The EGM approved, amongst other items:
- The issuance of the Subsequent
Gilead Warrant B
- The renewal of the company’s
authorized capital by up to 20% of the share capital
All documents related to the AGM and EGM can be
consulted on our website. The minutes of the meetings will be made
available in due course.
About GalapagosWe are a
biotechnology company with operations in Europe and the US
dedicated to developing transformational medicines for more years
of life and quality of life. Focusing on high unmet medical needs,
we synergize compelling science, technology, and collaborative
approaches to create a deep pipeline of best-in-class small
molecules, CAR-T therapies, and biologics in oncology and
immunology. With capabilities from lab to patient, including a
decentralized CAR-T manufacturing network, we are committed to
challenging the status quo and delivering results for our patients,
employees and shareholders. For additional information, please
visit www.glpg.com or follow us on LinkedIn or X (formerly
Twitter).
For further information, please
contact:
Media
inquiries:Marieke Vermeersch +32 479 490
603 media@glpg.com Jennifer Wilson + 44 7539
359 676media@glpg.com |
Investor
inquiries:Sofie Van Gijsel +1 781 296
1143ir@glpg.comSandra Cauwenberghs +32 495 58 46
63ir@glpg.com |
Forward-looking statements
This release may contain forward-looking statements. Such
forward-looking statements are not guarantees of future results.
These statements speak only as of the date of publication of this
release. We expressly disclaim any obligation to update any
forward-looking statements in this release, unless specifically
required by law or regulation.
Disclaimer The contents of our
website, including the annual report for the financial year 2023
and the reports prepared by the Board of Directors and the
statutory auditor at the occasion of the extraordinary
shareholders’ meeting, and any other website that may be accessed
from our website, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.
Galapagos (LSE:GLPG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Nov 2023 to Nov 2024